| 1 | Front Behav Neurosci 2009 -1 3: 3 |
|---|---|
| PMID | 19503748 |
| Title | Comprehensive behavioral phenotyping of ryanodine receptor type 3 (RyR3) knockout mice: decreased social contact duration in two social interaction tests. |
| Abstract | Dynamic regulation of the intracellular Ca2+ concentration is crucial for various neuronal functions such as synaptic transmission and plasticity, and gene expression. Ryanodine receptors (RyRs) are a family of intracellular calcium release channels that mediate calcium-induced calcium release from the endoplasmic reticulum. Among the three RyR isoforms,RYR3is preferentially expressed in the brain especially in the hippocampus and striatum. To investigate the behavioral effects ofRYR3deficiency, we subjectedRYR3knockout (RYR3- / -)小鼠行为测试的电池。RYR3-/- mice exhibited significantly decreased social contact duration in two different social interaction tests, where two mice can freely move and make contacts with each other. They also exhibited hyperactivity and mildly impaired prepulse inhibition and latent inhibition while they did not show significant abnormalities in motor function and working and reference memory tests. These results indicate thatRYR3has an important role in locomotor activity and social behavior. |
| SCZ Keywords | schizophrenia |
| 2 | Psychiatr. Genet. 2012 Feb 22: 1-14 |
| PMID | 21970977 |
| Title | Multiple genes in the 15q13-q14 chromosomal region are associated with schizophrenia. |
| Abstract | The chromosomal region, 15q13-q14, including the ?7 nicotinic acetylcholine receptor gene, CHRNA7, is a replicated region forschizophrenia. This study fine-mapped genes at 15q13-q14 to determine whether the association is unique to CHRNA7. Family-based and case-control association studies were performed on Caucasian-non-Hispanic and African-American individuals from 120 families as well as 468 individual patients withschizophreniaand 144 well-characterized controls. Single-nucleotide polymorphism (SNP) markers were genotyped, and association analyses carried out for the outcomes ofschizophrenia, smoking, and smoking inschizophrenia. Three genes were associated withschizophreniain both ethnic populations: TRPM1, KLF13, andRYR3. Two SNPs in CHRNA7 were associated withschizophreniain African-Americans, and a second SNP in CHRNA7 was significant for an association with smoking and smoking inschizophreniain Caucasians. Results of these studies support association of the 15q13-q14 region withschizophrenia. The broad positive association suggests that more than one 15q gene may be contributing to the disorder, either in combination or through a regulatory mechanism. |
| SCZ Keywords | schizophrenia |
| 3 | Expert Opin Drug Discov 2013 Dec 8: 1515-27 |
| PMID | 24147578 |
| Title | Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach. |
| Abstract | Neuropharmacology research in glutamate-modulating drugs supports their development and use in the management of neuropsychiatric disorders, including major depression, Alzheimer's disorder andschizophrenia. Concomitantly, there is a growing use of these agents used in the treatment of obsessive-compulsive disorder (OCD). This article provides a review of glutamate-modulating drugs used in the treatment of OCD. Specifically, the authors examine riluzole, N-acetylcysteine, d-cycloserine, glycine, ketamine, memantine and acamprosate as treatments. Furthermore, recent genetic epidemiology research findings are presented with a focus on the positional candidate genes SLC1A1 (a glutamate transporter), ADAR3 (an RNA-editing enzyme),RYR3(a Ca(2+) channel), PBX1 (a homeobox transcription factor) and a GWAS candidate gene, DLGAP1 (a protein interacting with post-synaptic density). These genetic findings are submitted to a curated bioinformatics database to conform a biological network for discerning potential pharmacological targets. In the genetically informed network, known genes and identified key connecting components, including DLG4 (a developmental gene), PSD-95 (a synaptic scaffolding protein) and PSEN1 (presenilin, a regulator of secretase), conform a group of potential pharmacological targets. These potential targets can be explored, in the future, to deliver new therapeutic approaches to OCD. There is also the need to develop a better understanding of neuroprotective mechanisms as a foundation for future OCD drug discovery. |
| SCZ Keywords | schizophrenia |